Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis episode artwork

EPISODE · May 15, 2026 · 21 MIN

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

from The IMID Forum · host The Immune-Mediated Inflammatory Disease Forum

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

NOW PLAYING

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

0:00 21:55

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The IMID Forum?

This episode is 21 minutes long.

When was this The IMID Forum episode published?

This episode was published on May 15, 2026.

What is this episode about?

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab...

Can I download this The IMID Forum episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!